newsfilter
← Latest News
GlobeNewswire·

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE,